Yüklüyor......
Oral Paricalcitol for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease
Secondary hyperparathyroidism (SHPT) is commonly seen in patients with chronic kidney disease (CKD). Even in early CKD, parathyroid hormone (PTH) levels are elevated, maintaining mineral homeostasis at the cost of long-term bone health. One potent stimulus for PTH secretion is a deficiency of active...
Kaydedildi:
| Asıl Yazarlar: | , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Dove Medical Press
2006
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1936265/ https://ncbi.nlm.nih.gov/pubmed/18360604 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|